Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02883062 2025-10-16

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01149083 2025-08-15

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Phase 2 Completed

77 enrolled 17 charts

Breast

Breast Neoplasms

NCT00520975 2025-03-28

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase 3 Terminated

96 enrolled 16 charts

Breast

Breast Neoplasms

NCT01237067 2019-12-17

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Phase 1 Completed

77 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT01445418 2019-10-22

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Phase 1 Completed

103 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01238133 2015-09-04

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Phase 1 Terminated

14 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00077376 2014-05-21

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

Phase 2 Completed

61 enrolled 12 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00002627 2014-01-10

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Phase 1/2 Unknown

30 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00002628 2014-01-10

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1/2 Unknown

50 enrolled

Breast

Breast Neoplasms

NCT00012311 2014-01-06

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

Phase 2 Unknown

Breast

Breast Neoplasms

NCT00002780 2013-12-19

Biological Therapy in Treating Women With Metastatic Breast Cancer

Phase 1/2 Unknown

60 enrolled

Breast

Breast Neoplasms

NCT00002616 2013-09-20

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Phase 1 Unknown

36 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00321633 2013-08-26

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

Phase 2 Completed

148 enrolled

BreastGynecologic

Breast Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

NCT00004900 2013-05-30

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2 Completed

Breast

Breast Neoplasms

NCT00004906 2013-05-30

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2 Completed

Breast

Breast Neoplasms

NCT00008203 2013-02-04

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

Phase 3 Completed

Breast

Breast Neoplasms

Clinical Trials

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

Biological Therapy in Treating Women With Metastatic Breast Cancer

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer